We are pleased to announce an important MEFISTO publication: Our article "Biofunctionalization of 3D printed collagen with bevacizumab-loaded microparticles targeting pathological angiogenesis" has just been published in the Journal of Controlled Release.
Highlights of this publication include the following:
- Release of bevacizumab from PLGA microparticles can be controlled.
- Degradation of bevacizumab during in vitro release was observed.
- Bevacizumab-loaded microparticles reduce angiogenesis in a 3D cellular model.
- Complex biomimicking structures by 3D printing microparticles-loaded collagen.
This work involved 4 MEFISTO partners: The University of Santiago de Compostela, the UMC Utrecht, the Consiglio Nationale delle Ricerche Napoli and Geistlich Pharma joined forces for this great result.
Enjoy reading!
Driving meniscus health forward
Driving meniscus health forward